{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T17:15:47Z","timestamp":1792602947286,"version":"4.5.0"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T00:00:00Z","timestamp":1570838400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1007\/s10549-019-05464-w","type":"journal-article","created":{"date-parts":[[2019,10,12]],"date-time":"2019-10-12T07:48:51Z","timestamp":1570866531000},"page":"275-285","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Efficacy and toxicity of extended aromatase inhibitors after adjuvant aromatase inhibitors-containing therapy for hormone-receptor-positive breast cancer: a literature-based meta-analysis of randomized trials"],"prefix":"10.1007","volume":"179","author":[{"given":"Xiaoying","family":"Qian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"GuoDong","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuanjian","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3801-3902","authenticated-orcid":false,"given":"Wu","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,10,12]]},"reference":[{"issue":"5","key":"5464_CR1","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1159\/000439462","volume":"10","author":"L Rossi","year":"2015","unstructured":"Rossi L, Pagani O (2015) The modern landscape of endocrine therapy for premenopausal women with breast cancer. Breast Care 10(5):312\u2013315","journal-title":"Breast Care"},{"key":"5464_CR2","doi-asserted-by":"publisher","first-page":"1687","DOI":"10.1016\/S0140-6736(05)66544-0","volume":"365","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2005","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687\u20131717","journal-title":"Lancet"},{"key":"5464_CR3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"The Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2011","unstructured":"The Early Breast Cancer Trialists\u2019 Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient level meta-analysis of randomised trials. Lancet 378:771\u2013784","journal-title":"Lancet"},{"key":"5464_CR4","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/S0140-6736(15)61074-1","volume":"386","author":"The Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"The Early Breast Cancer Trialists\u2019 Collaborative Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomized trials. Lancet 386:1341\u20131352","journal-title":"Lancet"},{"issue":"9","key":"5464_CR5","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1200\/JCO.2015.62.3504","volume":"34","author":"M Colleoni","year":"2016","unstructured":"Colleoni M, Sun Z, Price KN et al (2016) Annual hazard rates of recurrence for breast cancer during 24 years of follow-up: results from the International Breast Cancer Study Group Trials I to V. J Clin Oncol 34(9):927\u2013935","journal-title":"J Clin Oncol"},{"key":"5464_CR6","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1056\/NEJMoa032312","volume":"349","author":"PE Goss","year":"2003","unstructured":"Goss PE, Ingle JN, Martino S et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793\u20131802","journal-title":"N Engl J Med"},{"key":"5464_CR7","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1200\/JCO.2007.14.0228","volume":"26","author":"EP Mamounas","year":"2008","unstructured":"Mamounas EP, Jeong JH, Wickerham DL et al (2008) Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial. J Clin Oncol 26:1965\u20131971","journal-title":"J Clin Oncol"},{"key":"5464_CR8","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1016\/S0140-6736(12)61963-1","volume":"381","author":"C Davies","year":"2013","unstructured":"Davies C, Pan H, Godwin J et al (2013) Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial. Lancet 381:805\u2013816","journal-title":"Lancet"},{"issue":"Supplement 1","key":"5464_CR9","first-page":"18","volume":"31","author":"RG Gray","year":"2013","unstructured":"Gray RG, Rea D, Handley K et al (2013) aTTom: long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. J Clin Oncol 31(Supplement 1):18","journal-title":"J Clin Oncol"},{"key":"5464_CR10","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1200\/JCO.2006.08.8054","volume":"25","author":"M Kaufmann","year":"2007","unstructured":"Kaufmann M, Jonat W, Hilfrich J et al (2007) Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol 25:2664\u20132670","journal-title":"J Clin Oncol"},{"key":"5464_CR11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.ctrv.2017.08.008","volume":"60","author":"H Goldvaser","year":"2017","unstructured":"Goldvaser H, AlGorashi I, Ribnikar D et al (2017) Efficacy of extended adjuvant therapy with aromatase inhibitors in early breast cancer among common clinicopathologically defined subgroups: a systematic review and meta-analysis. Cancer Treat Rev 60:53\u201359","journal-title":"Cancer Treat Rev"},{"key":"5464_CR12","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.critrevonc.2012.09.013","volume":"86","author":"MJ Higgins","year":"2013","unstructured":"Higgins MJ, Liedke PE, Goss PE (2013) Extended adjuvant endocrine therapy in hormone dependent breast cancer: the paradigm of the NCIC-CTG MA.17\/BIG 1-97 trial. Crit Rev Oncol Hematol 86:23\u201332","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4 Supplement","key":"5464_CR13","first-page":"1","volume":"78","author":"M Gnant","year":"2018","unstructured":"Gnant M, Steger G, Greil R et al (2018) A prospective randomized multi-center phase-III trial of additional 2 versus additional 5 years of anastrozole after initial 5 years of adjuvant endocrine therapy\u2014results from 3,484 postmenopausal women in the ABCSG-16 trial. Cancer Res 78(4 Supplement):1","journal-title":"Cancer Res"},{"issue":"24","key":"5464_CR14","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1093\/jnci\/djm246","volume":"99","author":"R Jakesz","year":"2007","unstructured":"Jakesz R, Greil R, Gnant M et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24):1845\u20131853","journal-title":"J Natl Cancer Inst"},{"issue":"4 Supplement","key":"5464_CR15","first-page":"1","volume":"79","author":"S Ohtani","year":"2019","unstructured":"Ohtani S, Lijima K, Higaki K et al (2019) A prospective randomized multi-center open-label phase III trial of extending aromatase-inhibitor adjuvant therapy to 10 years-Results from 1697 postmenopausal women in the N-SAS BC 05 trial: Arimidex extended adjuvant randomized study (AERAS). Cancer Res 79(4 Supplement):1","journal-title":"Cancer Res"},{"issue":"11","key":"5464_CR16","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1016\/S1470-2045(17)30600-9","volume":"18","author":"VCG Tjan-Heijnen","year":"2017","unstructured":"Tjan-Heijnen VCG, van Hellemond IEG, Peer PGM et al (2017) Extended adjuvant aromatase inhibition after sequential endocrine therapy (DATA): a randomised, phase 3 trial. Lancet Oncol 18(11):1502\u20131511","journal-title":"Lancet Oncol"},{"issue":"1","key":"5464_CR17","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/jnci\/djx134","volume":"110","author":"EJ Blok","year":"2018","unstructured":"Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E et al (2018) Optimal duration of extended adjuvant endocrine therapy for early breast cancer; results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst 110(1):40\u201348","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"5464_CR18","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1093\/annonc\/mdw055","volume":"27","author":"N Zdenkowski","year":"2016","unstructured":"Zdenkowski N, Forbes JF, Boyle FM et al (2016) Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial. Ann Oncol 27(5):806\u2013812","journal-title":"Ann Oncol"},{"issue":"3","key":"5464_CR19","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1056\/NEJMoa1604700","volume":"375","author":"PE Goss","year":"2016","unstructured":"Goss PE, Ingle JN, Pritchard KI et al (2016) Extending aromatase-inhibitor adjuvant therapy to 10 years. N Engl J Med 375(3):209\u2013219","journal-title":"N Engl J Med"},{"issue":"1","key":"5464_CR20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/S1470-2045(18)30621-1","volume":"20","author":"EP Mamounas","year":"2019","unstructured":"Mamounas EP, Bandos H, Lembersky BC et al (2019) Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology\/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 20(1):88\u201399","journal-title":"Lancet Oncol"},{"key":"5464_CR21","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1200\/JCO.2009.26.3756","volume":"28","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Prestrud AA, Seidenfeld J et al (2010) American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol 28:3784\u20133796","journal-title":"J Clin Oncol"},{"key":"5464_CR22","doi-asserted-by":"publisher","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","volume":"24","author":"A Goldhirsch","year":"2013","unstructured":"Goldhirsch A, Winer EP, Coates AS et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer. Ann Oncol 24:2206\u20132223","journal-title":"Ann Oncol"},{"key":"5464_CR23","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1093\/jnci\/dji250","volume":"97","author":"PE Goss","year":"2005","unstructured":"Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262\u20131271","journal-title":"J Natl Cancer Inst"},{"issue":"9922","key":"5464_CR24","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","volume":"383","author":"J Cuzick","year":"1922","unstructured":"Cuzick J, Sestak I, Forbes JF et al (1922) Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet 383(9922):1041\u20131048","journal-title":"Lancet"},{"issue":"25","key":"5464_CR25","doi-asserted-by":"publisher","first-page":"2381","DOI":"10.1056\/NEJMoa1103507","volume":"364","author":"PE Goss","year":"2011","unstructured":"Goss PE, Ingle JN, Ales-Martinez JE et al (2011) Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med 364(25):2381\u20132391","journal-title":"N Engl J Med"},{"issue":"5","key":"5464_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13058-014-0446-2","volume":"16","author":"A Howell","year":"2014","unstructured":"Howell A, Anderson AS, Clarke RB et al (2014) Risk determination and prevention of breast cancer. Breast Cancer Res 16(5):1\u201319","journal-title":"Breast Cancer Res"},{"issue":"4","key":"5464_CR27","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.3390\/cancers4041146","volume":"4","author":"RL Rahman","year":"2012","unstructured":"Rahman RL, Pruthi S (2012) Chemoprevention of breast cancer: the paradox of evidence versus advocacy inaction. Cancers 4(4):1146\u20131160","journal-title":"Cancers"},{"key":"5464_CR28","doi-asserted-by":"publisher","first-page":"2959","DOI":"10.1038\/bjc.2013.671","volume":"109","author":"P Dubsky","year":"2013","unstructured":"Dubsky P, Brase JC, Jakesz R et al (2013) The EndoPredict score provides prognostic information on late distant metastases in ER+\/HER2- breast cancer patients. Br J Cancer 109:2959\u20132964","journal-title":"Br J Cancer"},{"key":"5464_CR29","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/S1470-2045(13)70387-5","volume":"14","author":"DC Sgroi","year":"2013","unstructured":"Sgroi DC, Sestak I, Cuzick J et al (2013) Prediction of late distant recurrence in patients with oestrogen-receptor-positive breast cancer: a prospective comparison of the breast-cancer index (BCI) assay, 21-gene recurrence score, and IHC4 in the TransATAC study population. Lancet Oncol 14:1067\u20131076","journal-title":"Lancet Oncol"},{"key":"5464_CR30","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1093\/annonc\/mdt494","volume":"25","author":"M Gnant","year":"2014","unstructured":"Gnant M, Filipits M, Greil R et al (2014) Predicting distant recurrence in receptor-positive breast cancer patients with limited clinicopathological risk: using the PAM50 risk of recurrence score in 1478 postmenopausal patients of the ABCSG-8 trial treated with adjuvant endocrine therapy alone. Ann Oncol 25:339\u2013345","journal-title":"Ann Oncol"},{"key":"5464_CR31","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1200\/JCO.2012.46.1558","volume":"31","author":"M Dowsett","year":"2013","unstructured":"Dowsett M, Sestak I, Lopez-Knowles E et al (2013) Comparison of PAM50 risk of recurrence score with oncotype DX and IHC4 for predicting risk of distant recurrence after endocrine therapy. J Clin Oncol 31:2783\u20132790","journal-title":"J Clin Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10549-019-05464-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-019-05464-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T23:44:41Z","timestamp":1602373481000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10549-019-05464-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,10,12]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["5464"],"URL":"https:\/\/doi.org\/10.1007\/s10549-019-05464-w","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,10,12]]},"assertion":[{"value":"17 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 October 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors. Ethical approval was not applicable for this systematic review and meta-analysis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}